ArticleCancer management and research2026
Upregulated lncRNA AK058003 in Tumor-Educated Platelets and Plasma as Liquid Biopsy Biomarkers for Esophageal Cancer.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Esophageal cancer (EC) ranks thirteenth in incidence and seventh in cancer-related mortality worldwide in 2024, with an estimated 494,000 new cases and 442,000 deaths, and esophageal squamous cell carcinoma (ESCC) remains the predominant histological subtype in China. Endoscopic biopsy and serum markers (SCCA, CA 19-9, CEA) have limited sensitivity or are invasive. This study evaluated the diagnostic potential of platelet and plasma lncRNA AK058003 in EC. Patients and Methods: Platelet and plasma lncRNA AK058003 expression was quantified by quantitative real-time PCR in 64 EC patients and 64 healthy controls. Diagnostic performance was assessed by ROC curve analysis. Correlations with clinicopathological parameters were analyzed. Results: Tumor-educated platelet (TEP) and plasma lncRNA AK058003 were significantly upregulated in EC patients (P = 0.0042 and P < 0.0001, respectively). Plasma lncRNA AK058003 showed an AUC of 0.83 (sensitivity 82.8%, specificity 76.6%), whereas TEP lncRNA AK058003 yielded an AUC of 0.65 (sensitivity 64.1%, specificity 60.9%). TEP lncRNA AK058003 expression was significantly higher in T3-T4 than T1-T2 stages (P = 0.0025) and correlated with tumor size (P = 0.0017). Conclusion: Both TEP and plasma lncRNA AK058003 were significantly upregulated in EC. Plasma lncRNA AK058003 demonstrated promising diagnostic performance (AUC 0.83, sensitivity 82.8%, specificity 76.6%), while TEP lncRNA AK058003 overexpression correlated with tumor size, supporting their potential as non-invasive liquid-biopsy biomarkers for EC diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.